Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – Race Oncology

Executive interview – Race Oncology

Race Oncology is developing bisantrene, which had been the subject of over 40 clinical trials in the 1980s and 1990s as part of Lederle’s search for a safer anthracycline chemotherapy. Despite positive responses in a variety of cancers, especially AML (it was even approved for the treatment of AML in France, but never commercialised), development stopped after Lederle was sold to Wyeth and then Wyeth to Pfizer. Race will be developing bisantrene initially for relapsed/refractory AML and expects to start a pivotal trial for approval in the US around the end of 2018.

< Previous
Next >

You may also be interested in these:

Healthcare

Recce Pharmaceuticals – executive interview

TMT

VEON – executive interview with CFO Joop Brakenhoff

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free